GLP-1 peptides did something unusual: in roughly five years, they turned a niche diabetes drug class into the most-discussed metabolic intervention of the decade. Here is what they actually are, what the published research shows so far, and what you should understand before treating any of it as personally relevant.

What GLP-1 peptides actually are

GLP-1 stands for glucagon-like peptide-1. It is a hormone your gut releases after you eat. Its job is small but important: it nudges your pancreas to release insulin, slows how fast food leaves your stomach, and sends a satiety signal to your brain. Natural GLP-1 lasts only a few minutes in your bloodstream before enzymes break it down — which is why early research focused on how to make it stable enough to be useful as a drug.

GLP-1 receptor agonists — molecules that activate the same receptor for much longer — are the result. Semaglutide (sold as Ozempic, Wegovy, and Rybelsus) and tirzepatide (Mounjaro, Zepbound) are the most familiar. Newer compounds like retatrutide and survodutide are still in clinical trials.

Why the conversation changed

Two things happened at the same time.

First, the trial data showed weight-loss numbers no prior pharmacological intervention had reached. In the STEP trials, semaglutide produced roughly 15% body-weight reduction over 68 weeks. In the SURMOUNT trials, tirzepatide at the highest dose produced roughly 20% over 72 weeks. For context, older anti-obesity drugs were lucky to reach single digits.

Second, telehealth providers, public supply shortages, and social media made GLP-1s culturally visible in a way that diabetes drugs had never been.

The result is a real shift in how obesity is framed clinically — less “willpower,” more “appetite regulation circuitry” — paired with a much messier shift in how people actually try to access these compounds.

What the research shows

The published evidence is strongest in three areas:

  • Weight loss. Randomized trials consistently show 12–22% reduction at one year on the higher doses of semaglutide and tirzepatide. Drop-out from side effects is meaningful — often 5–10% of trial participants.
  • Cardiovascular outcomes. The SELECT trial showed semaglutide reduced major cardiovascular events by about 20% in overweight or obese adults without diabetes over roughly three years. That re-framed GLP-1s as a metabolic-cardiovascular drug class, not just a weight-loss class.
  • Diabetes management. This is the original use case and the evidence base goes back decades.

Areas where the picture is less clear:

  • Long-term outcomes past 4–5 years have limited data.
  • What happens after stopping — most trials show meaningful weight regain within a year of discontinuation.
  • Lean muscle mass — a meaningful share of total loss appears to come from muscle rather than fat. How much that matters in the long run is still being studied.
  • Bone mineral density, pregnancy, and pediatric use are open questions.

The caveats

A few things to keep in mind before any of this becomes a personal decision.

  • GLP-1s approved for humans are prescription drugs. Ozempic, Wegovy, Mounjaro, Zepbound, and Rybelsus are FDA-approved medications that require a clinician’s prescription. They are not supplements and they are not legally sold over the counter.
  • Compounded GLP-1s sit in a different regulatory zone. During the recent shortages, compounding pharmacies were temporarily allowed to produce semaglutide and tirzepatide. As supplies normalized, FDA enforcement on the compounded market has tightened significantly.
  • “Research peptides” are a separate category. Some online vendors sell GLP-1 peptides labeled strictly for laboratory research and explicitly not for human use. That labeling is a legal posture, not a workaround — it puts the buyer outside the regulated drug supply chain, with no clinical-grade quality, purity, or dose verification.
  • Side effects are real and common. Nausea is the most reported. Pancreatitis, gallbladder issues, and gastroparesis signals are less common but documented. Hypoglycemia risk rises sharply when combined with insulin or sulfonylureas.
  • This is not medical advice. Decisions about whether GLP-1 medication is right for you belong with a clinician who knows your full history.

Where to learn about availability

Readers who want to dig deeper into the peptide research literature can do so through Best Days — which is operated by this site’s editor — which carries research-grade peptides intended for laboratory use, in areas like recovery, longevity, and metabolic health. Best Days does not sell GLP-1 compounds such as semaglutide or tirzepatide. Research peptides are explicitly not for human consumption and are not a substitute for prescription medication; they exist for academic and independent research only. For clinical access to FDA-approved GLP-1 medications, talk to your physician or a licensed telehealth provider.

Editor’s note: Biohack Library’s editor also operates Best Days. The link above reflects that relationship. We disclose this because reader trust requires it. This article is editorial commentary on publicly available research, not medical advice.